|
|
|
Volumn , Issue 63, 2004, Pages 1-4
|
|
Bevacizumab for advanced colorectal cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAMPTOTHECIN;
DRUG DERIVATIVE;
FLUOROURACIL;
FOLINIC ACID;
MONOCLONAL ANTIBODY;
VASCULOTROPIN;
ARTICLE;
CANADA;
CLINICAL TRIAL;
COLORECTAL TUMOR;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
PATHOLOGY;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
CANADA;
CLINICAL TRIALS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
COLORECTAL NEOPLASMS;
DRUG APPROVAL;
FLUOROURACIL;
HUMANS;
LEUCOVORIN;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
VASCULAR ENDOTHELIAL GROWTH FACTORS;
|
|
EID: 16544388464
PISSN: 14886324
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
